Loading...
01/10 05:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed strong product launches with significant revenue, robust market opportunities, and a solid cash position. Despite management's reluctance to share specific trends, the Q&A indicated positive sentiment about repeat prescribers and market potential. The lack of revenue guidance and potential competition are concerns, but the overall performance and market opportunities outweigh these risks. With a market cap of $1.7 billion, the positive sentiment and strong financials suggest a stock price increase in the range of 2% to 8% over the next two weeks.
RevuForge Net Revenue $20,000,000 (N/A) - This is the first full quarter of the launch, reflecting strong demand and a high unmet patient need.
Nyktymbo Net Revenue $13,600,000 (N/A) - This revenue was recorded for the first two months of the joint launch, indicating strong uptake and demand.
Collaboration Loss from Nyktymbo $200,000 (N/A) - This reflects the company's share of the net commercial loss, which is expected to convert to a positive revenue contribution quickly.
Cash and Equivalents $602,100,000 (N/A) - This strong cash position supports the company's ongoing operations and growth initiatives.
Market Opportunity for RevuForge $750,000,000 (N/A) - This represents the estimated market opportunity for patients with relapsed or refractory acute leukemia with a KMT2A translocation.
Total Addressable Market for Nyktymbo $1.5 to $2 billion (N/A) - This is the estimated market for chronic GVHD patients requiring three or more lines of therapy.
RevuForge Net Revenue: Syndax recorded $20,000,000 in RevuForge net revenue for the first full quarter of the launch.
Nyktymvo Net Revenue: Our partner, Insight, recorded $13,600,000 in net revenue for the first two months of our joint launch of Nyktymbo.
Total Net Sales: Combined $34,000,000 in net sales from RevuForge and Nyktymbo.
sNDA Submission: In April, we submitted a supplemental new drug application (sNDA) to the FDA for RevuForge for relapsed or refractory mutant NPM1 AML.
EVOLVE-two Trial: Initiated the EVOLVE-two trial, the first pivotal frontline trial of a menin inhibitor.
Market Opportunity for RevuForge: The current indication for RevuForge targets an estimated 2,000 patients in the US, representing a $750,000,000 market opportunity.
Market Opportunity for Nyktymvo: The current indication for Nyktymvo targets 6,500 chronic GVHD patients in the US, representing a $1.5 to $2 billion total addressable market.
Cash Position: Syndax has $602,100,000 in cash and equivalents as of March 31.
Formulary Coverage for RevuForge: As of March, formal coverage policies were in place for approximately 72% of all managed care lives.
Patient Access: Patients are receiving medication within a few days of receiving a prescription, ahead of industry benchmarks.
Strategic Focus: Syndax is focused on ensuring that no appropriate patient is left behind and is engaging all key stakeholders.
Clinical Guidelines Inclusion: Expecting RevuForge to be included in clinical guidelines for the treatment of relapsed or refractory mutant MPM1 AML.
Financial Risks: Syndax Pharmaceuticals reported a net revenue of $20,000,000 for RevuForge and $13,600,000 for Nictimvo, indicating a reliance on successful product launches for financial stability. Any delays or issues in these launches could impact revenue projections.
Regulatory Risks: The company is pursuing an sNDA for RevuForge, which is subject to FDA review. Any unfavorable outcomes or delays in the approval process could hinder market access and revenue generation.
Market Competition: Syndax is aware of potential competition from other targeted therapies entering the market, which could affect their market share and pricing strategies.
Supply Chain Challenges: The company has established a limited distribution model to ensure patient access, but any disruptions in the supply chain could impact the availability of their products.
Economic Factors: The overall economic environment, including healthcare spending and reimbursement policies, could influence the adoption and sales of Syndax's products.
Clinical Trial Risks: The success of ongoing clinical trials, such as EVOLVE-two, is critical for future product approvals. Any adverse results could significantly impact the company's pipeline and market position.
Patient Access Risks: The company has a patient assistance program, but any changes in insurance coverage or patient eligibility could affect access to their therapies.
RevuForge Net Revenue: Syndax recorded $20,000,000 in RevuForge net revenue for the first full quarter of the launch.
Nyktymvo Net Revenue: Our partner, Insight, recorded $13,600,000 in net revenue for the first two months of our joint launch of Nyktymbo.
Cash Position: Syndax has $602,100,000 in cash and equivalents as of March 31.
EVOLVE-two Trial: Initiated the first pivotal frontline trial of a menin inhibitor, EVOLVE II, enrolling newly diagnosed patients.
sNDA Submission: Submitted a supplemental new drug application for RevuForge for priority review.
Market Opportunity: The current indication for RevuForge targets an estimated 2,000 patients in the US, representing a $750,000,000 market opportunity.
Nictimbo Market Opportunity: The current indication for Nictimbo targets 6,500 chronic GVHD patients in the US, representing a $1.5 to $2 billion total addressable market.
Future Revenue Expectations: Expect Nictimbo to quickly convert to a positive revenue contribution.
Profitability Outlook: Expect cash, combined with anticipated RevuForge gross margin contribution, to enable the company to reach profitability.
FDA Approval Timeline: Expect RevuForge to be the first menin inhibitor approved in the frontline setting.
Clinical Guidelines Inclusion: Expect RevuForge to be included in clinical guidelines for the treatment of relapsed or refractory mutant MPM1 AML.
RevuForge Net Revenue: $20,000,000 in net revenue for the first full quarter of launch.
Nictimbo Net Revenue: $13,600,000 in net revenue for the first two months of launch.
Collaboration Loss from Nictimbo: $200,000 as Syndax's share of the net commercial loss.
Cash Position: $602,100,000 in cash and equivalents as of March 31.
Market Opportunity for RevuForge: Estimated $750,000,000 market opportunity for relapsed or refractory acute leukemia with KNT2A translocation.
Market Opportunity for Nictimbo: Estimated $1.5 to $2 billion total addressable market for chronic GVHD patients requiring three or more lines of therapy.
The earnings call summary highlights strong financial performance, product development, and market strategy, with optimistic guidance and shareholder return plans. The Q&A section provides additional positive insights, such as excellent payer access and a consistent safety profile for Revuforj. The strategic plan indicates significant growth opportunities, including market expansion and profitability outlook. Considering the company's strong market position, upcoming product approvals, and positive financial health, the stock is likely to see a positive movement in the short term.
The earnings call highlights strong revenue growth for both Revuforj and Niktimvo, with positive physician and patient feedback. The company expects profitability with existing resources and stable expenses. The Q&A section provides confidence in FDA approval and market expansion, particularly with the NPM1 label expansion. Although management avoided specific guidance, the overall sentiment is positive with strong financial performance and optimistic future outlooks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
